OmniAb (OABI) Competitors

$2.37 +0.08 (+3.49%)

Closing price 04:00 PM Eastern

Extended Trading

$2.40 +0.03 (+1.10%)

As of 07:58 PM Eastern

OABI vs. NUTX, ABSI, CRTO, EFOR, and RSKD

Should you buy OmniAb stock or one of its competitors? MarketBeat compares OmniAb with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OmniAb include Nutex Health (NUTX), Absci (ABSI), Criteo (CRTO), ASGN (EFOR), and Riskified (RSKD). These companies are all part of the "business services" industry.

How does OmniAb compare to Nutex Health?

OmniAb (NASDAQ:OABI) and Nutex Health (NASDAQ:NUTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

In the previous week, OmniAb and OmniAb both had 1 articles in the media. Nutex Health's average media sentiment score of 0.00 beat OmniAb's score of -0.29 indicating that Nutex Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OmniAb	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nutex Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

72.1% of OmniAb shares are held by institutional investors. Comparatively, 5.3% of Nutex Health shares are held by institutional investors. 9.8% of OmniAb shares are held by company insiders. Comparatively, 44.7% of Nutex Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nutex Health has a net margin of 10.95% compared to OmniAb's net margin of -187.59%. Nutex Health's return on equity of 23.50% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	-187.59%	-20.31%	-18.10%
Nutex Health	10.95%	23.50%	10.47%

OmniAb has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market. Comparatively, Nutex Health has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market.

Nutex Health has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Nutex Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$18.67M	18.38	-$64.78M	-$0.46	N/A
Nutex Health	$875.26M	0.99	$70.79M	$12.94	9.77

OmniAb currently has a consensus price target of $3.00, indicating a potential upside of 26.58%. Nutex Health has a consensus price target of $205.00, indicating a potential upside of 62.20%. Given Nutex Health's stronger consensus rating and higher possible upside, analysts plainly believe Nutex Health is more favorable than OmniAb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nutex Health	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Nutex Health beats OmniAb on 12 of the 15 factors compared between the two stocks.

How does OmniAb compare to Absci?

Absci (NASDAQ:ABSI) and OmniAb (NASDAQ:OABI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

OmniAb has a net margin of -187.59% compared to Absci's net margin of -6,450.76%. OmniAb's return on equity of -20.31% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Absci	-6,450.76%	-66.32%	-57.01%
OmniAb	-187.59%	-20.31%	-18.10%

Absci has a beta of 2.36, suggesting that its share price is 136% more volatile than the broader market. Comparatively, OmniAb has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market.

Absci presently has a consensus price target of $7.53, suggesting a potential upside of 62.28%. OmniAb has a consensus price target of $3.00, suggesting a potential upside of 26.58%. Given Absci's stronger consensus rating and higher probable upside, research analysts clearly believe Absci is more favorable than OmniAb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

OmniAb has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Absci	$2.80M	258.18	-$115.18M	-$0.83	N/A
OmniAb	$18.67M	18.38	-$64.78M	-$0.46	N/A

In the previous week, Absci had 11 more articles in the media than OmniAb. MarketBeat recorded 12 mentions for Absci and 1 mentions for OmniAb. Absci's average media sentiment score of 1.08 beat OmniAb's score of -0.29 indicating that Absci is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Absci	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OmniAb	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

52.1% of Absci shares are held by institutional investors. Comparatively, 72.1% of OmniAb shares are held by institutional investors. 10.5% of Absci shares are held by insiders. Comparatively, 9.8% of OmniAb shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Absci and OmniAb tied by winning 8 of the 16 factors compared between the two stocks.

How does OmniAb compare to Criteo?

OmniAb (NASDAQ:OABI) and Criteo (NASDAQ:CRTO) are both small-cap business services companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

In the previous week, Criteo had 1 more articles in the media than OmniAb. MarketBeat recorded 2 mentions for Criteo and 1 mentions for OmniAb. OmniAb's average media sentiment score of -0.29 beat Criteo's score of -0.53 indicating that OmniAb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OmniAb	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Criteo	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Criteo has a net margin of 6.06% compared to OmniAb's net margin of -187.59%. Criteo's return on equity of 14.98% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	-187.59%	-20.31%	-18.10%
Criteo	6.06%	14.98%	8.25%

OmniAb presently has a consensus target price of $3.00, suggesting a potential upside of 26.58%. Criteo has a consensus target price of $27.94, suggesting a potential upside of 63.04%. Given Criteo's stronger consensus rating and higher possible upside, analysts clearly believe Criteo is more favorable than OmniAb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Criteo	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

72.1% of OmniAb shares are owned by institutional investors. Comparatively, 94.3% of Criteo shares are owned by institutional investors. 9.8% of OmniAb shares are owned by insiders. Comparatively, 1.5% of Criteo shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Criteo has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Criteo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$18.67M	18.38	-$64.78M	-$0.46	N/A
Criteo	$1.94B	0.44	$144.60M	$2.14	8.01

OmniAb has a beta of 0.07, indicating that its share price is 93% less volatile than the broader market. Comparatively, Criteo has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Summary

Criteo beats OmniAb on 13 of the 16 factors compared between the two stocks.

How does OmniAb compare to ASGN?

OmniAb (NASDAQ:OABI) and ASGN (NYSE:EFOR) are both small-cap business services companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

ASGN has a net margin of 2.46% compared to OmniAb's net margin of -187.59%. ASGN's return on equity of 10.30% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	-187.59%	-20.31%	-18.10%
ASGN	2.46%	10.30%	4.94%

ASGN has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than ASGN, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$18.67M	18.38	-$64.78M	-$0.46	N/A
ASGN	$3.98B	0.19	$113.50M	$2.26	8.34

OmniAb currently has a consensus price target of $3.00, suggesting a potential upside of 26.58%. ASGN has a consensus price target of $35.67, suggesting a potential upside of 89.31%. Given ASGN's higher probable upside, analysts clearly believe ASGN is more favorable than OmniAb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
ASGN	4 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

72.1% of OmniAb shares are owned by institutional investors. Comparatively, 95.4% of ASGN shares are owned by institutional investors. 9.8% of OmniAb shares are owned by company insiders. Comparatively, 3.4% of ASGN shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, OmniAb had 1 more articles in the media than ASGN. MarketBeat recorded 1 mentions for OmniAb and 0 mentions for ASGN. ASGN's average media sentiment score of 0.00 beat OmniAb's score of -0.29 indicating that ASGN is being referred to more favorably in the news media.

Company	Overall Sentiment
OmniAb	Neutral
ASGN	Neutral

OmniAb has a beta of 0.07, indicating that its stock price is 93% less volatile than the broader market. Comparatively, ASGN has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

Summary

ASGN beats OmniAb on 11 of the 16 factors compared between the two stocks.

How does OmniAb compare to Riskified?

Riskified (NYSE:RSKD) and OmniAb (NASDAQ:OABI) are both small-cap business services companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

Riskified has a net margin of -5.17% compared to OmniAb's net margin of -187.59%. Riskified's return on equity of -3.91% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Riskified	-5.17%	-3.91%	-2.89%
OmniAb	-187.59%	-20.31%	-18.10%

Riskified has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, OmniAb has a beta of 0.07, indicating that its stock price is 93% less volatile than the broader market.

In the previous week, Riskified had 12 more articles in the media than OmniAb. MarketBeat recorded 13 mentions for Riskified and 1 mentions for OmniAb. Riskified's average media sentiment score of 0.49 beat OmniAb's score of -0.29 indicating that Riskified is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Riskified	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
OmniAb	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Riskified has higher revenue and earnings than OmniAb. Riskified is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Riskified	$344.64M	2.07	-$27.57M	-$0.11	N/A
OmniAb	$18.67M	18.38	-$64.78M	-$0.46	N/A

Riskified presently has a consensus price target of $5.96, suggesting a potential upside of 23.69%. OmniAb has a consensus price target of $3.00, suggesting a potential upside of 26.58%. Given OmniAb's stronger consensus rating and higher possible upside, analysts plainly believe OmniAb is more favorable than Riskified.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Riskified	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

59.0% of Riskified shares are held by institutional investors. Comparatively, 72.1% of OmniAb shares are held by institutional investors. 17.4% of Riskified shares are held by insiders. Comparatively, 9.8% of OmniAb shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Riskified beats OmniAb on 11 of the 16 factors compared between the two stocks.

Get OmniAb News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OABI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OABI vs. The Competition

Export

Metric	OmniAb	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$331.55M	$2.99B	$6.25B	$12.23B
Dividend Yield	N/A	1.96%	2.80%	5.27%
P/E Ratio	-5.15	17.04	20.79	25.04
Price / Sales	18.38	251.21	531.21	72.18
Price / Cash	N/A	57.15	43.09	54.25
Price / Book	1.31	4.39	9.81	6.83
Net Income	-$64.78M	$74.99M	$3.55B	$335.69M
7 Day Performance	28.11%	-4.89%	-2.07%	-2.03%
1 Month Performance	44.51%	-8.30%	-3.90%	-1.90%
1 Year Performance	52.90%	28.66%	29.39%	27.36%

OmniAb Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OABI OmniAb	2.6912 of 5 stars	$2.37 +3.5%	$3.00 +26.6%	+44.9%	$331.55M	$18.67M	N/A	7
NUTX Nutex Health	2.7979 of 5 stars	$135.48 +2.0%	$252.50 +86.4%	-28.6%	$914.39M	$875.26M	10.47	1,150
ABSI Absci	3.9929 of 5 stars	$5.36 -7.3%	$7.58 +41.4%	+71.9%	$901.13M	$2.80M	N/A	210	Positive News Gap Down
CRTO Criteo	4.7375 of 5 stars	$16.20 +0.6%	$28.39 +75.2%	-43.0%	$803.23M	$1.94B	7.57	3,649
EFOR ASGN	4.5996 of 5 stars	$17.84 -5.6%	$35.67 +99.9%	N/A	$776.79M	$3.98B	4.38	2,800

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OABI) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OmniAb (OABI) Competitors